Evaluating the Therapeutic Potential of Yemeni Shilajit from Dhamar, Ma’rib, and Raymah on Hemolytic Anemia in Rabbits: Effects on G6PD Activity, PCV, Hemoglobin, and RBC Count
Clicks: 1
ID: 311561
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #188 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Shilajit is a historically valued natural substance with promising but still preliminary scientific support for urinary and diabetic health, yet its growing popularity risks exploitation and exaggerated claims without rigorous human clinical validation. This study investigates the therapeutic effects of Yemeni Shilajit sourced from Dhamar, Ma'rib, and Raymah on hemolytic anemia experimentally induced in rabbits using phenylhydrazine.
Methods: Twelve male rabbits were divided into four groups: a control group and three treatment groups, each receiving Shilajit from one of the three regions. Anemia was induced via subcutaneous injection of phenylhydrazine hydrochloride, and treatment was administered orally at a dose of 125 to 250 mg/kg twice daily. Hematological parameters—including packed cell volume (PCV), hemoglobin concentration (Hb), red blood cell (RBC) count, and glucose-6- phosphate dehydrogenase (G-6-PD) activity—were evaluated at various intervals.
Results: showed that Shilajit from Dhamar and Raymah significantly increased PCV, Hb, RBC count, and G-6-PD enzyme activity (p < 0.05), suggesting notable anti-anemic effects and potential for restoring hematological parameters to near-normal levels. In contrast, Ma'rib Shilajit exhibited limited efficacy, with significant improvement only in hemoglobin levels. Phytochemical analysis confirmed the presence of essential amino acids and bioactive compounds, such as fulvic acid and dibenzo-α-pyrones, which likely contribute to Shilajit’s therapeutic action.
Conclusions: The study concludes that purified Shilajit from Dhamar and Raymah holds promise as a natural remedy for hemolytic anemia, supporting its traditional use and warranting further investigation for pharmacological applications.
| Reference Key |
jaadan2025evaluating
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bushra Jaadan, Wafa M. Al-Madhagi, Ali G. Al-kaf, Sami H. Alrabahi |
| Journal | Yemen Journal of Medicine |
| Year | 2025 |
| DOI |
10.63475/yjm.v4i2.0135
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.